Fundraising FoxViolet Therapeutics, Inc.
Cambridge, US · Founded 2021 · 7 known investors
Find your way into Violet Therapeutics, Inc.
Sign up to see every warm intro you have to Violet Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Violet Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Violet is a therapeutics company developing small molecule treatments for central nervous system diseases, using its proprietary C-to-C Engine platform to identify disease-relevant cell-to-cell interactions. Its lead program is a small molecule inhibitor of EphB3, a receptor tyrosine kinase involved in microglia-astrocyte interactions linked to glial dysfunction in neurodegenerative disease.
Founders & leadership
Investors · 7
How we know: Dementia Discovery's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: Dementia Discovery Fund's portfolio page · funding news · globenewswire.com · Not right? Tell us
How we know: Lifespan Vision Ventures's portfolio page · Not right? Tell us
How we know: Ono Venture Investment, Inc.'s portfolio page · globenewswire.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$7.4M disclosed across 1 of 2 rounds · 2023
- Undisclosed amountseed funding roundMay 2023
Dementia Discovery Fund (lead), UTEC (University of Tokyo Edge Capital Partners) (lead), Mass General Brigham Ventures (MGBV), Ono Venture Investment
Source ↗
▶$7.4MraisedMay 2023 · 4 investors · OtherRule 506(b)
- William E YelleExecutive Officer, Director
- Atsushi UsamiDirector
- Meredith FisherExecutive Officer, Director
- Jonathan BehrDirector
- Offering amount
- $11.5M
- Amount sold
- $7.4M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Violet Therapeutics, Inc. do?
- Violet is a therapeutics company developing small molecule treatments for central nervous system diseases, using its proprietary C-to-C Engine platform to identify disease-relevant cell-to-cell interactions. Its lead program is a small molecule inhibitor of EphB3, a receptor tyrosine kinase involved in microglia-astrocyte interactions linked to glial dysfunction in neurodegenerative disease.
- Who are Violet Therapeutics, Inc.'s investors?
- Violet Therapeutics, Inc.'s investors include Dementia Discovery, Dementia Discovery Fund, Lifespan Vision Ventures, Ono Venture Investment, Inc., SV Health Investors, UTEC.
- How much funding has Violet Therapeutics, Inc. raised?
- Violet Therapeutics, Inc. has disclosed $7.4M raised across 1 of its 2 known rounds.
- Where is Violet Therapeutics, Inc. headquartered?
- Violet Therapeutics, Inc. is headquartered in Cambridge, US.